Sept 23 (Reuters) - Moderna Inc MRNA.O:
MODERNA: POSITIVE PRELIM IMMUNOGENICITY DATA FOR 2025-2026 FORMULA OF MNEXSPIKE, WHICH TARGETS LP.8.1 VARIANT OF SARS-COV-2
MODERNA: PRELIM ANALYSIS SHOWED 2025-2026 FORMULA OF MNEXSPIKE GENERATED >16-FOLD INCREASE IN LP.8.1-NEUTRALIZING ANTIBODIES ACROSS AGE GROUPS
MODERNA: SAFETY PROFILE OF VACCINE CONSISTENT WITH PREVIOUS STUDIES
((Reuters.Briefs@thomsonreuters.com))